DiaSorin and Tecan to collaborate in new platform development
23 Junio 2017 - 12:25AM
Tecan Group AG / DiaSorin and Tecan to collaborate in new
platform development . Processed and transmitted by Nasdaq
Corporate Solutions. The issuer is solely responsible for the
content of this announcement.
Saluggia, Italy and Männedorf, Switzerland, June 23, 2017 - DiaSorin (FTSE
Italy Mid Cap: DIA) and Tecan Group (SIX Swiss Exchange: TECN)
announced today that they have agreed to collaborate in a
development under which DiaSorin will make use of Tecan's
Fluent® Laboratory
Automation Solution as its Nucleic Acid extraction platform.
The new platform will be used in combination with
the DiaSorin Liaison® MDX PCR
system to provide the customer with a complete sample to result
system for Molecular Diagnostics.
The Fluent platform, to be supplied through Tecan
Partnering, will be optimized for use with DiaSorin extraction
chemistry and automated PCR set up of the Liaison® MDX 96
well disc.
Fluent breaks new ground, delivering more capacity and increased
speed. The platform provides exceptional precision, throughput and
walkaway time.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory
instruments and solutions in biopharmaceuticals, forensics and
clinical diagnostics. The company specializes in the development,
production and distribution of automated workflow solutions for
laboratories in the life sciences sector. Its clients include
pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original
equipment manufacturer (OEM), Tecan is also a leader in developing
and manufacturing OEM instruments and components that are then
distributed by partner companies. Founded in Switzerland in 1980,
the company has manufacturing, research and development sites in
both Europe and North America and maintains a sales and service
network in 52 countries. In 2016, Tecan generated sales of
CHF 506 million (USD 511 million;
EUR 464 million). Registered shares of Tecan Group are
traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
About DiaSorin
Headquartered in Italy and listed in the FTSE Italia Mid Cap Index,
DiaSorin is a global leader in the In Vitro Diagnostics (IVD)
field. For over 40 years the Company has been developing, producing
and marketing reagent kits for IVD worldwide. Through constant
investments in research and development, and using its own
distinctive expertise in the field of immunodiagnostics to deliver
a high level of innovation, DiaSorin offers today the broadest
range of specialty tests available in the immunodiagnostics market
and new tests in the molecular diagnostics markets, which identify
DiaSorin Group as the IVD "diagnostics specialist".
For more information, please visit www.diasorin.com
For further information:
Tecan Group
Martin Brändle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com
DiaSorin
Riccardo
Fava
Investor Relations & Corporate Communication Senior
Director
Tel: +39 0161 487988
riccardo.fava@diasorin.it
DiaSorin
Ines Di Terlizzi
Investor Relator
Tel: +39 0161 487567
ines.diterlizzi@diasorin.it
Press Release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Tecan Group AG via Globenewswire
--- End of Message ---
Tecan Group AG
Seestrasse 103 Maennedorf Switzerland
ISIN: CH0012100191;